Select publications:

  1. BE Rolfe, I Blakey, O Squires, H Peng, NRB Boase, C Alexander, PG Parsons, GM Boyle, AK Whittaker and KJ Thurecht. 2014, J. Am. Chem. Soc. 136 (6), 2413-2419.
  2. CB Howard, N Fletcher, ZH Houston, AV Fuchs, NRB Boase, JD Simpson, LJ Raftery, T Ruder, ML Jones, CJ de Bakker, SM Mahler and KJ Thurecht. 2016. Overcoming Instability of Antibody-Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies. Adv. Healthcare. Mater. 5(16), 2055-2068.
  3. M Bjornmalm, KJ Thurecht, M Michael, AM Scott and F Caruso. 2017. Bridging Bio-Nano Science and Cancer Nanomedicine. ACS Nano. 11(10), 9594-9613.
  4. AV Fuchs, BWC Tse, AK Pearce, MC Yeh, NL Fletcher, SS Huang, WD Heston, AK Whittaker, PJ Russell and KJ Thurecht. 2015, Evaluation of Polymeric Nanomedicines Targeted to PSMA:Effect of Ligand on Targeting Efficiency. 16(10), 3235-3247.


We Use and Promote New/Emerging tools in Nanomedicine

  1. Access to one of only a handful of instruments that facilitate simultaneous PET-MRI for understanding nanomedicine efficacy in animal models.
  2. Development of comparative oncology as a more informative tool for understanding nanomedicine behaviour. This includes PET-CT and MRI of companion animals diagnosed with prostate, breast and brain cancer.